We are live on ! Find out more
TCM

Tang Capital Management Portfolio holdings

AUM $1.97B
1-Year Est. Return 125.1%
This Fund
S&P 500
This Quarter Est. Return
-3.24%
1 Year Est. Return
+125.1%
3 Year Est. Return
+474.48%
5 Year Est. Return
+595.08%
10 Year Est. Return
+2,831.44%
AUM
$709M
AUM Growth
+$29.4M
Cap. Flow
+$90.1M
Cap. Flow %
12.71%
Top 10 Hldgs %
39.27%
Holding
116
New
17
Increased
23
Reduced
16
Closed
10

Top Buys

Rank Stock Value
1
EQRX
EQRx, Inc. Common Stock
EQRX
+$21.6M
2
NTLA icon
Intellia Therapeutics
NTLA
+$15.4M
3
AVDL
Avadel Pharmaceuticals
AVDL
+$13.4M
4
NVCR icon
NovoCure
NVCR
+$11.3M
5
QURE icon
uniQure
QURE
+$8.42M

Top Sells

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$10.9M
2
COF icon
Capital One
COF
+$8.75M
3
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$4.67M
4
PYXS icon
Pyxis Oncology
PYXS
+$4.58M
5
PHAT icon
Phathom Pharmaceuticals
PHAT
+$3.58M

Sector Composition

Rank Sector Weight
1 Healthcare 94.04%
2 Financials 5.11%
3 Real Estate 0.78%
4 Consumer Discretionary 0.07%
5 Utilities 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIO icon
26
Bio-Rad Laboratories Class A
BIO
$9.42B
$8.6M 1.21%
24,000
+8,000
+50% +$3.09M
IFRX icon
27
InflaRx
IFRX
$271M
$8.42M 1.19%
2,824,353
-75,647
-3% -$288K
CTMX icon
28
CytomX Therapeutics
CTMX
$754M
$8.32M 1.17%
6,450,000
-150,000
-2% -$236K
DNTH icon
29
Dianthus Therapeutics
DNTH
$6.09B
$8.09M 1.14%
591,636
+212,886
+56% +$2.68M
NVCR icon
30
NovoCure
NVCR
$1.91B
$7.95M 1.12%
492,100
+392,100
+392% +$11.3M
MRNA icon
31
Moderna
MRNA
$23.6B
$7.92M 1.12%
76,700
– –
MRTX
32
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$7.84M 1.11%
180,000
+100,000
+125% +$3.57M
VSTM icon
33
Verastem
VSTM
$610M
$7.25M 1.02%
891,514
-248,486
-22% -$2.39M
ALT icon
34
Altimmune
ALT
$599M
$7.15M 1.01%
2,750,000
– –
ZYME icon
35
Zymeworks
ZYME
$1.67B
$6.97M 0.98%
1,100,000
– –
BCAB icon
36
BioAtla
BCAB
$5.74M
$6.42M 0.91%
75,568
+2,086
+3% +$266K
QURE icon
37
uniQure
QURE
$3.22B
$6.28M 0.89%
+935,800
New +$8.42M
AUPH icon
38
Aurinia Pharmaceuticals
AUPH
$2.11B
$5.83M 0.82%
750,000
+600,000
+400% +$5.87M
CGEM icon
39
Cullinan Oncology
CGEM
$1.14B
$5.62M 0.79%
621,138
+171,138
+38% +$1.78M
EQC
40
DELISTED
Equity Commonwealth
EQC
$5.51M 0.78%
300,000
+200,000
+200% +$3.88M
TECX
41
Tectonic Therapeutic
TECX
$606M
$5.41M 0.76%
292,724
+67,307
+30% +$1.19M
AMRN
42
Amarin Corp
AMRN
$303M
$5.39M 0.76%
293,126
-61,874
-17% -$1.34M
LENZ
43
LENZ Therapeutics
LENZ
$168M
$5M 0.71%
288,089
-9,857
-3% -$171K
ADMA icon
44
ADMA Biologics
ADMA
$2.22B
$4.87M 0.69%
1,360,000
+100,000
+8% +$385K
DVAX
45
DELISTED
Dynavax Technologies
DVAX
$4.43M 0.63%
300,000
– –
INSM icon
46
Insmed
INSM
$28.6B
$4.2M 0.59%
166,203
– –
C icon
47
Citigroup
C
$226B
$4.11M 0.58%
100,000
– –
ADAP
48
DELISTED
Adaptimmune Therapeutics
ADAP
$4.03M 0.57%
5,166,954
+279,716
+6% +$235K
QNCX icon
49
Quince Therapeutics
QNCX
$29.5M
$3.92M 0.55%
17,494
-572
-3% -$149K
VBTX
50
DELISTED
Veritex Holdings
VBTX
$3.77M 0.53%
210,000
– –
1
2
3 4 5

Similar funds

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return

Tang Capital Management's Q3 2023 Portfolio in Review

As of Q3 2023, Tang Capital Management held 116 positions worth $709M, up 4.3% from $679M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tang Capital Management deployed $90.1M of net new capital in Q3 2023, opening 17 new positions and adding to 23 existing holdings. Its largest new stake was EQRx, Inc. Common Stock: 10,086,110 shares worth $22.4M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Financials and Real Estate.

On the sell side, the largest reduction was bluebird bio, an estimated $10.9M trimmed.

  • Tang Capital Management's largest Q3 2023 buy was EQRx, Inc. Common Stock: 10,086,110 shares worth $22.4M.
  • Tang Capital Management added most to NovoCure in Q3 2023, an estimated $11.3M increase.
  • Tang Capital Management's biggest Q3 2023 reduction was bluebird bio, cutting an estimated $10.9M.
  • Tang Capital Management fully exited Capital One in Q3 2023, selling an estimated $8.75M.
  • Tang Capital Management's ten largest holdings make up 39% of its $709M portfolio in Q3 2023.
  • Tang Capital Management opened 17 new positions and closed 10 in Q3 2023.
  • Tang Capital Management's portfolio value rose 4.3% quarter-over-quarter to $709M.

Based on Tang Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.